PMID- 22321592
OWN - NLM
STAT- MEDLINE
DCOM- 20121231
LR  - 20120210
IS  - 0253-9624 (Print)
IS  - 0253-9624 (Linking)
VI  - 45
IP  - 10
DP  - 2011 Oct
TI  - [Effect of highly active anti-retroviral therapy on prevention of mother to child 
      transmission of HIV and on infant growth and development].
PG  - 912-5
AB  - OBJECTIVE: To identify the effect of highly active anti-retroviral therapy 
      (HAART) on prevention of mother to child transmission (PMTCT) of HIV and on 
      infant growth and development. METHODS: A total of 16 HIV-infected women or 
      pregnant women selected in this study received HAART before or 18 - 24 weeks 
      after pregnancy. The treatment included taking Zidovudine (AZT) 0.3 g each time, 
      twice a day, Lamivudine (3TC) 0.3 g each time, once a day and Nevirapine (NVP) 
      0.2 g each time, twice a day or Efavirenz (EFV) 0.6 g each time, once a day, as 
      well as labor intervention and artificial feeding. The growth index for 17 
      infants from HIV-infected mothers (experimental group) and 16 normal infants 
      (control group) were observed for 18 months. Neonatal hemoglobin (Hb), liver and 
      kidney function, serum iron and calcium were detected at neonatal period and at 
      12(th) month, respectively. RESULTS: All the pregnant women were in good 
      conditions and had tolerance with HAART. The birth weight, length and Apgar score 
      of the newborns in the experimental group were (3.5 +/- 0.9) kg, (54.2 +/- 3.8) cm 
      and 7 - 10 scores respectively, however those in the control group were (3.6 +/- 
      0.8) kg, (55.6 +/- 3.6) cm and 8 - 10 scores (t(weight) = 1.01, t(length) = 6.98, P 
      > 0.05). Weight and length of infants in experimental group were (9.36 +/- 1.8) kg 
      and (76.3 +/- 2.7) cm at 12(th) month, while those in control group were (9.86 +/- 
      2.5) kg and (76.8 +/- 2.9) cm (t(weight) = 0.83, t(length) = 1.00, P > 0.05). The 
      level of Hb in experimental group was (126.2 +/- 16.7) g/L, and was (148.6 +/- 20.5) 
      g/L in control group (t = -5.89, P = 0.11). At 12(th) month, the levels of Hb and 
      the total bilirubin (TB) were (125.9 +/- 19.8) g/L and (11.7 +/- 3.5) micromol/L in 
      experimental group; and those in the control group were (130.1 +/- 18.7) g/L and 
      (13.2 +/- 3.7) micromol/L (t(Hb) = -3.82, t(TB) = -2.14, P > 0.05). Serum iron and 
      calcium were (25.4 +/- 5.7) micromol/L and (26.4 +/- 7.2) micromol/L at neonatal period and 
      were (2.3 +/- 0.6) mol/L and (2.8 +/- 0.6) mol/L at 12(th) month in experimental 
      group, while those were (26.2 +/- 4.9) micromol/L and (28.1 +/- 6.9) micromol/L at neonatal 
      period and were (2.6 +/- 0.5) mol/L and (3.1 +/- 0.5) mol/L at 12(th) month in the 
      control group (t(Fe) = 0.80 and t(Ca) = -3.00 in neonatal period, t(Fe) = -1.50 
      and t(Ca) = -1.00 at 12(th) month, P > 0.05). All infants of HIV-infected mothers 
      were not infected with HIV when they were 18 months old. CONCLUSION: HAART can 
      prevent mother to child transmission of HIV and it was not found to influence the 
      baby's growth and development in this study.
FAU - He, Yan
AU  - He Y
AD  - Infectious Disease and AIDS Research Center, Second Xiangya Hospital, Central 
      South University, Changsha 410011, China.
FAU - Luo, Yan
AU  - Luo Y
FAU - Ding, Yi-ling
AU  - Ding YL
FAU - Zheng, Yu-huang
AU  - Zheng YH
FAU - Li, Jing
AU  - Li J
FAU - Huang, Jian
AU  - Huang J
FAU - Li, Jie-min
AU  - Li JM
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Yu Fang Yi Xue Za Zhi
JT  - Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
JID - 7904962
SB  - IM
MH  - Adult
MH  - *Antiretroviral Therapy, Highly Active
MH  - Child Development/*drug effects
MH  - Female
MH  - HIV
MH  - HIV Infections/*prevention & control/transmission
MH  - Humans
MH  - Infant, Newborn
MH  - Infectious Disease Transmission, Vertical/*prevention & control
MH  - *Maternal Exposure
MH  - Pregnancy
MH  - Pregnancy Complications, Infectious/*drug therapy/virology
EDAT- 2012/02/11 06:00
MHDA- 2013/01/01 06:00
CRDT- 2012/02/11 06:00
PHST- 2012/02/11 06:00 [entrez]
PHST- 2012/02/11 06:00 [pubmed]
PHST- 2013/01/01 06:00 [medline]
PST - ppublish
SO  - Zhonghua Yu Fang Yi Xue Za Zhi. 2011 Oct;45(10):912-5.